These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26768512)

  • 1. Neoadjuvant use of ipilimumab in locally advanced melanoma.
    Howie LJ; Tyler DS; Salama AK
    J Surg Oncol; 2015 Dec; 112(8):841-3. PubMed ID: 26768512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. News from the melanoma sessions of the European Cancer Congress 2017.
    Rutkowski P; Kozak K
    BMC Med; 2017 Mar; 15(1):57. PubMed ID: 28302128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the treatment of melanoma.
    Lacy KE; Karagiannis SN; Nestle FO
    Clin Med (Lond); 2012 Apr; 12(2):168-71. PubMed ID: 22586796
    [No Abstract]   [Full Text] [Related]  

  • 4. Ipilimumab in advanced melanoma: reports of long-lasting responses.
    Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
    Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
    Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B
    J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ipilimumab lesson in melanoma: achieving long-term survival.
    Delyon J; Maio M; Lebbé C
    Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
    McKean MA; Amaria RN
    Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
    Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
    G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
    Seremet T; Koch A; Jansen Y; Schreuer M; Wilgenhof S; Del Marmol V; Liènard D; Thielemans K; Schats K; Kockx M; Van Criekinge W; Coulie PG; De Meyer T; van Baren N; Neyns B
    J Transl Med; 2016 Aug; 14(1):232. PubMed ID: 27484791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1511-21. PubMed ID: 23181437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for the management of advanced melanoma: the next steps.
    Zikich D; Schachter J; Besser MJ
    Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study and treatment of locally advanced melanoma].
    Moreno-Ramírez D; de la Cruz L; Ferrándiz L; Camacho FM
    Actas Dermosifiliogr; 2009 Nov; 100(9):767-79. PubMed ID: 19889298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab: a guide to its use in advanced melanoma.
    Lyseng-Williamson KA; Sanford M
    Am J Clin Dermatol; 2012 Oct; 13(5):349-54. PubMed ID: 22849352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
    McDermott D; Lebbé C; Hodi FS; Maio M; Weber JS; Wolchok JD; Thompson JA; Balch CM
    Cancer Treat Rev; 2014 Oct; 40(9):1056-64. PubMed ID: 25060490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma.
    Ponto J; Bell RB
    Oral Maxillofac Surg Clin North Am; 2022 May; 34(2):315-324. PubMed ID: 35491081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant therapy for high-risk bulky regional melanoma.
    Tarhini AA; Pahuja S; Kirkwood JM
    J Surg Oncol; 2011 Sep; 104(4):386-90. PubMed ID: 21858833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current advances and perspectives in the treatment of advanced melanoma.
    Livingstone E; Zimmer L; Vaubel J; Schadendorf D
    J Dtsch Dermatol Ges; 2012 May; 10(5):319-25. PubMed ID: 22432863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for melanoma.
    Cuevas LM; Daud AI
    Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives.
    Testori AAE; Ribero S; Indini A; Mandalà M
    Am J Clin Dermatol; 2019 Dec; 20(6):817-827. PubMed ID: 31177507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.